Forty Seven, Inc. (OTC:FTSV)
Industry: PharmaceuticalsMajor

Forty Seven Inc., a clinical-stage immuno-oncology company, focuses on developing therapies to activate macrophages for the treatment of cancer. It is developing 5F9, a humanized IgG4 subclass monoclonal antibody against CD47 that is in Phase 1b/2 clinical trials used for the treatment of cancer; FSI-189, an antibody that binds to SIRPa; and FSI-174, an anti-cKIT antibody. The company was formerly known as CD47 Sciences, Inc. Forty Seven Inc. was incorporated in 2014 and is headquartered in Menlo Park, California.

Current Quote*
Last: $17.935
Change: -0.695
Book: $4.171
Volume: 18,637

As Of: 04/24 13:20 ET
*Quotes delayed by 20min.

Graphs for FTSV

3 Month Graph

6 Month Graph

1 Year Graph